The original selection criteria and generation of human iPS cells from lymphocytes of subjects carrying MOR N40D were described previously (Halikere et al., 2019). This study utilized isogenic human stem cell lines that were both generated and validated previously (Halikere et al., 2019). Briefly, CRISPR/Cas9 genome editing was employed to convert rs1799971 in the 03SF subject iPS cell line from homozygous minor allele (GG) to major allele (AA). The two subclones used in this study were C12 (GG118, unedited control) and A10 (AA118, edited), both of which had been processed through identical CRISPR/Cas9 procedures. A detailed description describing the generation and characterization of the isogenic iPS cell lines are provided in Halikere et al., 2019.
